WENDY PRATT: Open Payments
NPI 1225021207 · COVINGTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,541 in 70 payments from 11 companies in 2025. Trend: 2023 $855 · 2024 $743 · 2025 $1,541
Food & beverage: $1,473Education: $68
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 31 | $353 |
| GENZYME CORPORATION | 10 | $318 |
| AstraZeneca Pharmaceuticals LP | 9 | $218 |
| Regeneron Healthcare Solutions, Inc. | 9 | $198 |
| Viatris Specialty LLC | 4 | $172 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $125 |
| Amgen Inc. | 2 | $68 |
| Actelion Pharmaceuticals US, Inc. | 1 | $40 |
| Insmed, Inc. | 1 | $18 |
| Merck Sharp & Dohme LLC | 1 | $16 |
Products named: DUPIXENT, NUCALA, YUPELRI, AIRSUPRA, TRELEGY ELLIPTA, FASENRA, UPTRAVI, TEZSPIRE.
Industry payments across LA — which companies pay providers there.
